HEALTHJun 18 · 08:30 UTCSTAT NEWSAlex Hogan

What’s next for GLP-1 weight loss drugs?

GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are popular, prompting competitors like Pfizer and Amgen to develop similar products. The article discusses market competition and strategies by Novo Nordisk and Eli Lilly to maintain dominance in the weight loss drug sector.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Novo NordiskorganizationEli LillyorganizationPfizerorganizationAmgenorganizationWegovytopicZepboundtopicGLP-1 weight loss drugstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJun 13 · 12:00 UTC
Drugmakers race to find a place in the next wave of obesity drugs
BUSINESSMay 11 · 20:28 UTC
Hims Sales Miss on Rising Competition for Weight-Loss Drugs
BUSINESSApr 14 · 15:02 UTC
Novo Nordisk partners with OpenAI in weight loss drug race
HEALTHJun 7 · 23:35 UTC
The Wegovy pill is still dominating the GLP-1 pill market
HEALTHMay 28 · 13:26 UTC
STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more